Clindamycin Injection

Contraindicated

Clindamycin Injection Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Clindamycin Injection Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Clindamycin Injection Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details

Major

Clindamycin Injection Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Clindamycin Injection Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Clindamycin Injection Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Clindamycin Injection Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Injection Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Clindamycin Injection Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Injection Ceritinib Zykadia Increased exposure of CYP3A substrate Details Clindamycin Injection Cholera Vaccine, Live Reduced immune response to the cholera vaccine Details Clindamycin Injection Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Clindamycin Injection Conivaptan Vaprisol Increased CYP3A substrate exposure Details Clindamycin Injection Crizotinib Xalkori Increased exposure of the CYP3A substrate Details Clindamycin Injection Daridorexant Increased CYP3A4 substrate with NTI exposure Details Clindamycin Injection Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Clindamycin Injection Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Injection Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Injection Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Clindamycin Injection Exenatide Bydureon Reduced oral antibiotics absorption and reduced efficacy of oral antibiotics Details Clindamycin Injection Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Clindamycin Injection Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Clindamycin Injection Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Clindamycin Injection Imatinib Gleevec Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Injection Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Clindamycin Injection Lanreotide Altered exposure to CYP3A4 substrate Details Clindamycin Injection Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Injection Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Clindamycin Injection Letermovir Prevymis Increased CYP3A substrate exposure Details Clindamycin Injection Lonafarnib Zokinvy Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Clindamycin Injection Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Clindamycin Injection Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Clindamycin Injection Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Clindamycin Injection Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Clindamycin Injection Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Clindamycin Injection Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Clindamycin Injection Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Clindamycin Injection Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Clindamycin Injection Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Injection Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details